Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Exploring the Brain - Gut Microbiota - Kidney Interactive Damage Mechanisms Underlying Cognitive Decline in Patients With IgA Nephropathy Using Ultra-high Field Magnetic Resonance Imaging

24 maja 2026 zaktualizowane przez: Tang-Du Hospital

Brain-Gut-Kidney Axis in IgA Nephropathy Cognitive Decline: An Ultra-High Field MRI Study

IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Its progression is often accompanied by cognitive decline, manifesting as multi-dimensional cognitive deficits in areas such as memory, attention, and executive function. Cognitive decline in patients with IgAN severely impacts their quality of life, yet the underlying central nervous system (CNS) damage mechanisms remain unclear, and no effective interventions are currently available. Recent domestic and international studies suggest a potential interactive damage network involving the brain, gut microbiota, and kidneys in patients with chronic kidney disease (CKD). Therefore, exploring the causes of cognitive decline in IgAN patients from the perspective of multi-organ interactive damage, identifying brain injury targets and aberrant gut microbial communities that correlate with changes in renal function, is crucial for the development of effective and precise clinical interventions.

Our team has been conducting MRI research on brain injury associated with cognitive decline in CKD since 2015. We have extensive experience in studying brain structure, function, metabolism, and perfusion in patients with end-stage renal disease (ESRD). Our work has been supported by numerous grants, including the General Program and Young Scientists Fund of the National Natural Science Foundation of China (NSFC) and the Key R&D Program of Shaanxi Province, yielding a series of scientific achievements. The etiological heterogeneity and high prevalence of IgAN suggest that we should focus on the central mechanisms of cognitive decline in this specific patient population. The recent clinical application of 7.0 Tesla (T) ultra-high field MRI provides critical hardware support, enabling us to investigate sub-millimeter-level structural and functional abnormalities in the early stages of IgAN.

This study aims to recruit 100 patients with IgAN from the Department of Nephrology and 100 demographically matched healthy controls from the local community. We will collect serum, stool samples, and brain ultra-high field MRI data from both patients and controls. By integrating these data with assessments from multi-dimensional neurocognitive scales, we will explore the potential brain-gut-kidney damage characteristics underlying cognitive decline in IgAN patients from the perspectives of serum metabolomics, fecal gut microbiota analysis, and multi-modal ultra-high field brain MRI analysis.

Przegląd badań

Status

Zakończony

Typ studiów

Obserwacyjny

Zapisy (Rzeczywisty)

200

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Xi'an
      • Shanxi, Xi'an, Chiny, 713800
        • Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły

Akceptuje zdrowych ochotników

Tak

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

IgA Nephropathy (IgAN) Group: A cohort of 100 patients diagnosed with IgA nephropathy, confirmed by pathological biopsy.

Healthy Control (HC) Group: A cohort of 100 healthy volunteers who are demographically matched to the patient group in terms of age, gender, and educational attainment.

Opis

Inclusion Criteria:

  1. Right-handed individuals, age 18-60 years;
  2. Diagnosis of IgA nephropathy confirmed by renal biopsy.

Exclusion Criteria:

  1. Secondary IgA nephropathy, such as that associated with systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, hepatitis B or C infection, or drug-induced causes.
  2. History of kidney transplantation, hemodialysis, or peritoneal dialysis.
  3. Acute cerebrovascular event within the past 3 months; a history of severe traumatic brain injury, brain tumor, stroke, or encephalomalacia that has resulted in identifiable lesions or significant asymmetry of cranial anatomy.
  4. Malignant tumors; a history of intestinal surgery; or irritable bowel syndrome (IBS).
  5. Use of antibiotics, steroids, immunosuppressants, or microbiota-based preparations within the past month.
  6. Inflammatory bowel disease (IBD); or the presence of symptoms such as diarrhea, abdominal pain, or IBS-like symptoms within the past two weeks.
  7. History of alcohol dependence.
  8. Current use of psychiatric medications, such as antidepressants or anxiolytics.
  9. Loss of hearing or vision.
  10. Pregnancy or lactation.
  11. Current participation in another clinical trial.

Contraindications for 7.0T MRI Presence of ferromagnetic implants in the body (e.g., cardiac pacemakers, defibrillators, neurostimulators, aneurysm clips, cochlear implants, or any other metallic foreign bodies).

Non-ferromagnetic implants (e.g., titanium alloy, orthopedic implants), intrauterine devices (IUDs), or non-removable dental prosthetics (including dental implants).

Metallic foreign bodies in the eye or body (e.g., metal fragments, shrapnel, or metallic debris), such as in individuals with a history of welding or metal-related injuries.

Tattoos or permanent makeup (e.g., on eyebrows or lips) acquired within the last month.

Claustrophobia. Fever. Inclusion Criteria for the Healthy Control Group

All healthy controls must meet the following criteria:

  1. Right-handed, aged 18-60 years;
  2. All physiological indicators within the normal range, with no signs of disease;
  3. No family history of psychiatric or neurological disorders.

Exclusion Criteria for the Healthy Control Group

  1. History of cranial surgery, brain tumor, traumatic brain injury, stroke, or encephalomalacia resulting in significant asymmetry of cranial anatomy;
  2. History of psychiatric disorders, alcohol dependence, or central nervous system diseases;
  3. Presence of metallic foreign bodies in the body or claustrophobia, making them unsuitable for MRI scanning;
  4. History of hypertension, diabetes, or hyperlipidemia;
  5. Hearing or vision impairment that would affect communication during the MRI scan or the completion of cognitive assessments.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
HC
IgAN

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Gut Microbiome Metagenomic Characteristics
Ramy czasowe: April 2025 to March 2027

Description: Taxonomic composition, relative abundance of microbial taxa, alpha diversity indices (Shannon, Simpson), and functional pathway profiles derived from shotgun metagenomic sequencing of fecal samples.

Unit/Scale: Relative abundance (%), Shannon index, Simpson index, normalized pathway abundance.

April 2025 to March 2027
Functional Neuroimaging Indices
Ramy czasowe: April 2025 to March 2027

Description: Resting-state functional magnetic resonance imaging (rs-fMRI) derived metrics, including functional connectivity (FC), amplitude of low-frequency fluctuation (ALFF), fractional ALFF (fALFF), and regional homogeneity (ReHo).

Unit/Scale: Standardized Z-scores, correlation coefficients.

April 2025 to March 2027
Cognitive Function Scores
Ramy czasowe: April 2025 to March 2027

Description: Cognitive performance assessed using the Montreal Cognitive Assessment (MoCA).

Scale/Range: 0-30 points. Interpretation: Higher scores indicate better cognitive function; lower scores indicate more severe cognitive impairment.

April 2025 to March 2027

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Serum Metabolomic and Biomarker Levels
Ramy czasowe: April 2025 to March 2027

Description: Quantitative analysis of serum metabolomic profiles, inflammatory factors (e.g., IL-6, TNF-α), and neurotransmitters (e.g., serotonin, dopamine) using targeted metabolomics assays.

Unit/Scale: pg/mL, ng/mL, or standardized relative concentration units.

April 2025 to March 2027
Fecal Gut Microbiome Analysis
Ramy czasowe: April 2025 to March 2027

Description: Taxonomic composition, alpha/beta diversity, and differential microbial taxa identified via 16S rRNA gene sequencing or shotgun metagenomic sequencing of fecal samples.

Unit/Scale: Relative abundance (%), Shannon index, Simpson index, Bray-Curtis dissimilarity.

April 2025 to March 2027
Memory Function (Cognitive Subdomain)
Ramy czasowe: April 2025 to March 2027

Description: Verbal memory assessed using the Auditory Verbal Learning Test (AVLT).

Scale/Range: 0-75 points (AVLT total recall score). Interpretation: Higher scores indicate better memory performance.

April 2025 to March 2027
Attention and Executive Function (Cognitive Subdomains)
Ramy czasowe: April 2025 to March 2027

Description: Attention and executive function assessed using the Stroop Color-Word Test and Trail Making Test (TMT).

Unit/Scale: Reaction time (seconds), completion time (seconds), number of errors.

Interpretation: Shorter completion time and fewer errors indicate better attention and executive function.

April 2025 to March 2027

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 kwietnia 2025

Zakończenie podstawowe (Rzeczywisty)

5 maja 2026

Ukończenie studiów (Rzeczywisty)

5 maja 2026

Daty rejestracji na studia

Pierwszy przesłany

12 maja 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

24 maja 2026

Pierwszy wysłany (Rzeczywisty)

1 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

1 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

24 maja 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Nefropatia IgA (IgAN)

Subskrybuj